Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin

被引:216
作者
Falzarano, Darryl [1 ]
de Wit, Emmie [1 ]
Martellaro, Cynthia [1 ]
Callison, Julie [1 ]
Munster, Vincent J. [2 ]
Feldmann, Heinz [1 ,3 ]
机构
[1] NIAID, Dis Modeling & Transmiss Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA
[2] NIAID, Virus Ecol Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada
来源
SCIENTIFIC REPORTS | 2013年 / 3卷
基金
美国国家卫生研究院;
关键词
ACUTE RESPIRATORY SYNDROME; SARS-COV INFECTION; SYNERGISTICALLY INHIBIT; FUNCTIONAL RECEPTOR; VIRUS; PHARMACOKINETICS; PNEUMONIA; OUTBREAK;
D O I
10.1038/srep01686
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The identification of a novel beta coronavirus, nCoV, as the causative agent of severe respiratory illness in humans originating in Saudi Arabia, Qatar and Jordan has raised concerns about the possibility of a coronavirus pandemic similar to that of SARS-CoV. As a definitive treatment regimen has never been thoroughly evaluated for coronavirus infections, there is an urgent need to rapidly identify potential therapeutics to address future cases of nCoV. To determine an intervention strategy, the effect of interferon-alpha 2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated. hCoV-EMC/2012 was sensitive to both interferon-alpha 2b and ribavirin alone in Vero and LLC-MK2 cells, but only at relatively high concentrations; however, when combined, lower concentrations of interferon-alpha 2b and ribavirin achieved comparable endpoints. Thus, a combination of interferon-alpha 2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.
引用
收藏
页数:6
相关论文
共 48 条
[1]  
[Anonymous], 2013, RESP CARE, V58, P18
[2]   Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever [J].
Bausch, Daniel G. ;
Hadi, Christiane M. ;
Khan, Sheik Humarr ;
Lertora, Juan J. L. .
CLINICAL INFECTIOUS DISEASES, 2010, 51 (12) :1435-1441
[3]   Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area [J].
Booth, CM ;
Matukas, LM ;
Tomlinson, GA ;
Rachlis, AR ;
Rose, DB ;
Dwosh, HA ;
Walmsley, SL ;
Mazzulli, T ;
Avendano, M ;
Derkach, P ;
Ephtimios, IE ;
Kitai, I ;
Mederski, BD ;
Shadowitz, SB ;
Gold, WL ;
Hawryluck, LA ;
Rea, E ;
Chenkin, JS ;
Cescon, DW ;
Poutanen, SM ;
Detsky, AS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2801-2809
[4]   Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy [J].
Brochot, Etienne ;
Castelain, Sandrine ;
Duverlie, Gilles ;
Capron, Dominique ;
Nguyen-Khac, Eric ;
Francois, Catherine .
ANTIVIRAL THERAPY, 2010, 15 (05) :687-695
[5]  
Buchholz U., 2013, EUROSURVEILLANCE B E, V18
[6]  
Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
[7]   In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J].
Chen, F ;
Chan, KH ;
Jiang, Y ;
Kao, RYT ;
Lu, HT ;
Fan, KW ;
Cheng, VCC ;
Tsui, WHW ;
Hung, IFN ;
Lee, TSW ;
Guan, Y ;
Peiris, JSM ;
Yuen, KY .
JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (01) :69-75
[8]   Treatment of SARS with human interferons [J].
Cinatl, J ;
Morgenstern, B ;
Bauer, G ;
Chandra, P ;
Rabenau, H ;
Doerr, HW .
LANCET, 2003, 362 (9380) :293-294
[9]  
Corman V. M., 2012, EUROSURVEILLANCE B E, V17
[10]   Extended Protection against Phlebovirus Infection Conferred by Recombinant Adenovirus Expressing Consensus Interferon (DEF201) [J].
Gowen, Brian B. ;
Ennis, Jane ;
Sefing, Eric J. ;
Wong, Min-Hui ;
Jung, Kie-Hoon ;
Turner, Jeffrey D. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (08) :4168-4174